On March 12, 2025, Dogwood Therapeutics entered into a Debt Exchange and Cancellation Agreement with Conjoint Inc., converting $19,926,891 in loans into 284.2638 shares of Series A-1 Preferred Stock, which can be converted into 10,000 shares of common stock each. Additionally, the company amended its Registration Rights Agreement and filed a Certificate of Designation for the Series A-1 Preferred Stock.